EBMT Annual Meeting – 2023 – Poster Presentation P249
Publications
April 23, 2023
Initial First-In-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplantation (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias
Trem-cel
Presented by: Benjamin Tomlinson, MD – University Hospitals Seidman Cancer Center